New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

Conservative supporters of government deregulation want to do away with state-imposed licensing requirements, a move genetic counselors say will harm patients.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

Ibex Prostate Detect is designed to help pathologists catch small and rare cancers in whole-slide images from tissue biopsies that they might've missed.

The biopharma company, which is developing cell therapies for cancers and autoimmune diseases, said it will use the proceeds for working capital.

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.